Table 4.

Associations between CYP17 genotype and breast cancer according to menopausal status and tumor stage

	A1A1	A1A2	A2A2	A1A2 and A2A2
Premenopausal
Controls, n (%)	100 (43.5)	99 (43.0)	31 (13.5)	130 (56.5)
Cases by stage
Local, n (%)	48 (43.6)	50 (45.5)	12 (10.9)	62 (56.4)
OR (95% CI)a	1.0	1.02 (0.61–1.71)	0.76 (0.35–1.66)b	0.96 (0.58–1.56)
Advanced, n (%)	41 (53.2)	30 (39.0)	6 (7.8)	36 (46.8)
OR (95% CI)a	1.0	0.63 (0.35–1.25)	0.43 (0.16–1.16)c	0.57 (0.32–1.01)
Postmenopausal
Controls, n (%)	127 (40.4)	150 (47.8)	37(11.8)	187 (59.6)
Cases by stage
Local, n (%)	93 (40.8)	105 (46.0)	30 (13.2)	135 (59.2)
OR (95% CI)a	1.0	1.01 (0.65–1.52)	1.07 (0.57–2.16)d	1.02 (0.68–1.53)
Advanced, n (%)	47 (35.6)	73 (55.3)	12 (9.1)	85 (64.4)
OR (95% CI)a	1.0	0.98 (0.59–1.64)	0.87 (0.37–2.05)e	0.97 (0.62–1.53)

^aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen. ^bP for trend = 0.591; ^cP for trend = 0.061; ^dP for trend = 0.835; ^eP for trend = 0.829.